Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of
standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate
anticoagulation strategy = low-dose low-molecular weight heparin [LMWH], ambulatory no
anticoagulation, i.e. placebo within this trial) in reduction of morbidity and mortality
endpoints in patients with COVID-19.